Femasys Change in Accounts Payable 2021-2025 | FEMY

Femasys change in accounts payable from 2021 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Femasys Change in Accounts Payable 2021-2025 | FEMY

Femasys change in accounts payable from 2021 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$241.7B
Amgen (AMGN)$155.8B
Gilead Sciences (GILD)$149.1B
Vertex Pharmaceuticals (VRTX)$101.5B
Bristol Myers Squibb (BMY)$97.4B
CSL (CSLLY)$86.1B
GSK (GSK)$79.8B
Regeneron Pharmaceuticals (REGN)$59.5B
Alnylam Pharmaceuticals (ALNY)$56.7B
Argenex SE (ARGX)$39.6B
BioNTech SE (BNTX)$27.1B
Insmed (INSM)$26B
Royalty Pharma (RPRX)$20.5B
Biogen (BIIB)$19.8B
Incyte (INCY)$16.8B
Illumina (ILMN)$15.5B
Genmab (GMAB)$14.5B
Genmab (GNMSF)$14.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.5B
Exelixis (EXEL)$10.4B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Verona Pharma American Depositary Share (VRNA)$9B
Bio-Techne Corp (TECH)$8.6B
Exact Sciences (EXAS)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Halozyme Therapeutics (HALO)$8B